InvestorsHub Logo
Followers 0
Posts 97
Boards Moderated 0
Alias Born 09/28/2016

Re: davidal66 post# 1921

Monday, 03/12/2018 10:33:39 PM

Monday, March 12, 2018 10:33:39 PM

Post# of 2099
These are all great points. The ovarian trial has an n=4 in comparator arm, and with rGBM miss, it is really hard to trust a not so well designed Ph2 ovarian trial.

Canning OVAL would require laying off several people - and I just wonder if he will be able to do that.

VB600 series (MOSPD2) is so early in development that even if they filed an IND by mid-2019, it would not reach a pivotal Ph3 until around 2024. For investors sitting in right now, you would wonder what is the point. There would be plenty time to come back in later years.

As always davidal, you have wise words. Thanks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News